- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Biomarkers as Tools in Management of Type 2 Inflammation
An expert in COPD delves into biomarkers indicative of type 2 inflammation and recommends diagnostic tests for assessing inflammation in COPD patients.
EP: 1.Navigating the Challenges of Respiratory Diseases
EP: 2.The Impact of Atopic Dermatitis and Prurigo Nodularis
EP: 3.Linking Type 2 Inflammation to Asthma and COPD
EP: 4.Impact of Exacerbations in Type 2 Inflammatory Respiratory Diseases
EP: 5.Type 2 Inflammation: The Link Between AD and PN
EP: 6.Personalizing Treatment Selection
EP: 7.Navigating Treatment Challenges in Chronic Skin Conditions
EP: 8.Role of Biologics in Dermatological Care
EP: 9.Biomarkers as Tools in Management of Type 2 Inflammation
EP: 10.Strategies to Manage Type 2 Inflammation in Respiratory Diseases
EP: 11.Addressing Unmet Needs and Emerging Agents
EP: 12.Future Directions for Type 2 Inflammation Management
EP: 13.Type 2 Inflammatory Diseases and Impact on Quality of Life
EP: 14.Type 2 Inflammation Biomarkers
EP: 15.How Type 2 Inflammation Influences Treatment Choices
EP: 16.Complications of Uncontrolled Disease and Management of Comorbidities
EP: 17.Patient Education and Emerging Therapies
EP: 18.Unmet Needs and Future Research
- What biomarkers can reliably assess the presence of type 2 inflammation as a contributing factor in asthma or COPD?
- How can absolute eosinophil count specifically be used as a tool in this population for regimen selection? Does this biomarker have a role in predicting treatment response or patient outcomes?
High HSP60 Expression Signals Poor Prognosis, Aggressive Tumors in Ovarian Cancer
January 16th 2025High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a prognostic biomarker.
Read More
Real-World Evidence Confirms the Benefits of JAK Inhibitors in Patients With Rheumatoid Arthritis
January 16th 2025This systematic review of real-world observational studies demonstrated the effectiveness of Janus kinase (JAK) inhibitors in improving treatment adherence, persistence, clinical outcomes, and patient-reported outcomes among US patients with rheumatoid arthritis.
Read More
